High Tumoral STMN1 Expression Is Associated with Malignant Potential and Poor Prognosis in Patients with Neuroblastoma

Background. Stathmin 1 (STMN1), a marker for immature neurons and tumors, controls microtubule dynamics by destabilizing tubulin. It plays an essential role in cancer progression and indicates poor prognosis in several cancers. This potential protein has not been clarified in clinical patients with neuroblastoma. Therefore, this study aimed to assess the clinical significance and STMN1 function in neuroblastoma with and without MYCN amplification. Methods. Using immunohistochemical staining, STMN1 expression was examined in 81 neuroblastoma samples. Functional analysis revealed the association among STMN1 suppression, cellular viability, and endogenous or exogenous MYCN expression in neuroblastoma cell lines. Result. High levels of STMN1 expression were associated with malignant potential, proliferation potency, and poor prognosis in neuroblastoma. STMN1 expression was an independent prognostic factor in patients with neuroblastoma. Furthermore, STMN1 knockdown inhibited neuroblastoma cell growth regardless of endogenous and exogenous MYCN overexpression. Conclusion. Our data suggest that assessing STMN1 expression in neuroblastoma could be a powerful indicator of prognosis and that STMN1 might be a promising therapeutic candidate against refractory neuroblastoma with and without MYCN amplification.

[1]  Z. Shao,et al.  Protein Phosphatase 1 Subunit PPP1R14B Stabilizes STMN1 to Promote Progression and Paclitaxel Resistance in Triple-Negative Breast Cancer , 2022, Cancer research.

[2]  Frederick S. Vizeacoumar,et al.  A Drug Repurposing Screen Identifies Fludarabine Phosphate as a Potential Therapeutic Agent for N-MYC Overexpressing Neuroendocrine Prostate Cancers , 2022, Cells.

[3]  G. C. Chan,et al.  Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma , 2022, Biomolecules.

[4]  W. Wang,et al.  Transcriptome dynamics of hippocampal neurogenesis in macaques across the lifespan and aged humans , 2021, Cell Research.

[5]  Wei Hu,et al.  PTEN loss promotes oncogenic function of STMN1 via PI3K/AKT pathway in lung cancer , 2021, Scientific Reports.

[6]  Zhe Zhang,et al.  CARMA3 Transcriptional Regulation of STMN1 by NF-κB Promotes Renal Cell Carcinoma Proliferation and Invasion , 2021, Technology in cancer research & treatment.

[7]  G. Goodall,et al.  Stathmin levels alter PTPN14 expression and impact neuroblastoma cell migration , 2019, British Journal of Cancer.

[8]  Dan Zhang,et al.  Association of STMN1 with survival in solid tumors: A systematic review and meta-analysis , 2019, The International journal of biological markers.

[9]  Yi-xuan Yang,et al.  Stathmin gene silencing suppresses proliferation, migration and invasion of gastric cancer cells via AKT/sCLU and STAT3 signaling. , 2019, International journal of oncology.

[10]  M. Madonna,et al.  Update on neuroblastoma. , 2019, Journal of pediatric surgery.

[11]  Zhou Wang,et al.  STMN1, a prognostic predictor of esophageal squamous cell carcinoma, is a marker of the activation of the PI3K pathway. , 2018, Oncology reports.

[12]  K. Shirabe,et al.  High STMN1 Expression Is Associated with Tumor Differentiation and Metastasis in Clinical Patients with Pancreatic Cancer. , 2018, Anticancer Research.

[13]  Y. Liu,et al.  MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast cancer via direct targeting of STMN1 , 2018, Cell Death & Disease.

[14]  H. Kuwano,et al.  Prognostic impact of stathmin 1 expression in patients with lung adenocarcinoma , 2017, The Journal of thoracic and cardiovascular surgery.

[15]  H. Kuwano,et al.  High STMN1 Expression is Associated with Cancer Progression and Chemo-Resistance in Lung Squamous Cell Carcinoma , 2017, Annals of Surgical Oncology.

[16]  J. Horiguchi,et al.  Stathmin1 expression is associated with aggressive phenotypes and cancer stem cell marker expression in breast cancer patients , 2017, International journal of oncology.

[17]  H. Kuwano,et al.  High stathmin 1 expression is associated with poor prognosis and chemoradiation resistance in esophageal squamous cell carcinoma. , 2017, International journal of oncology.

[18]  T. Oyama,et al.  High STMN1 level is associated with chemo-resistance and poor prognosis in gastric cancer patients , 2017, British Journal of Cancer.

[19]  O. Fadare,et al.  An immunohistochemical analysis of stathmin 1 expression in uterine smooth muscle tumors: differential expression in leiomyosarcomas and leiomyomas. , 2015, International journal of clinical and experimental pathology.

[20]  X. Bian,et al.  Systemic Delivery of MicroRNA-101 Potently Inhibits Hepatocellular Carcinoma In Vivo by Repressing Multiple Targets , 2015, PLoS genetics.

[21]  H. Kuwano,et al.  Stathmin1 regulates p27 expression, proliferation and drug resistance, resulting in poor clinical prognosis in cholangiocarcinoma , 2014, Cancer science.

[22]  Jing Zhao,et al.  c‐Myc‐mediated epigenetic silencing of MicroRNA‐101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma , 2014, Hepatology.

[23]  G. Blandino,et al.  Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells , 2014, Oncogene.

[24]  Wen-Ren Wu,et al.  Overexpression of stathmin 1 confers an independent prognostic indicator in nasopharyngeal carcinoma , 2014, Tumor Biology.

[25]  L. Yang,et al.  RNAi-mediated stathmin suppression reduces lung metastasis in an orthotopic neuroblastoma mouse model , 2014, Oncogene.

[26]  H. Feilotter,et al.  Stathmin 1 is a potential novel oncogene in melanoma , 2013, Oncogene.

[27]  M. Minden,et al.  Suspected leukemia oncoproteins CREB1 and LYL1 regulate Op18/STMN1 expression. , 2012, Biochimica et biophysica acta.

[28]  Sik Yoon,et al.  Hedgehog signaling regulates proliferation of prostate cancer cells via stathmin1 , 2010, Clinical and Experimental Medicine.

[29]  S. Kyo,et al.  Stathmin, a microtubule regulatory protein, is associated with hypoxia-inducible factor-1alpha levels in human endometrial and endothelial cells. , 2009, Endocrinology.

[30]  Barbara Hero,et al.  The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Shushan Rana,et al.  Stathmin 1: a novel therapeutic target for anticancer activity , 2008, Expert review of anticancer therapy.

[32]  B. Hero,et al.  Neuroblastoma , 2007, The Lancet.

[33]  M. Kavallaris,et al.  Neuronal-associated microtubule proteins class III beta-tubulin and MAP2c in neuroblastoma: role in resistance to microtubule-targeted drugs. , 2004, Molecular cancer therapeutics.

[34]  Gudrun Schleiermacher,et al.  Gene expression profiling of 1p35–36 genes in neuroblastoma , 2004, Oncogene.

[35]  D. Stram,et al.  Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  T. Nammoku,et al.  Identification and initial characterization of stathmin by the differential display method in nerve growth factor-treated PC12 cells. , 1998, European journal of endocrinology.

[37]  Rogier Versteeg,et al.  Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. , 1996, The New England journal of medicine.

[38]  J. Strahler,et al.  N-myc gene amplification in neuroblastoma is associated with altered phosphorylation of a proliferation related polypeptide (Op18). , 1990, Oncogene.